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New approaches to delay the progression of chronic renal failure. includes a progressive expansion of the tubulointerstit-
Background. The molecular cloning of many bone morpho- ium space and subsequent fibrosis. This expansion of
genetic proteins (BMP)-encoding genes and their identification the interstitial volume is the result of proliferation ofas transforming growth factor- (TGF-) relatives enhanced
fibroblasts within the interstitium, infiltration of the in-the interest in these molecules and allowed expression and
terstitium by monocytes, and the excess production offunctional studies to be performed.
Methods. Rats with ureteral obstruction were distributed into matrix within the interstitium, by all of these cells and
four groups. Group 1 received vehicle, group 2 received enala- by the tubule epithelial cells [3, 4]. This leads to an
pril 12.5 mg/kg body wt/day, group 3 received 50 or 300 g/
increased spatial separation of the peritubular capillarykg body wt BMP-7, and group 4 received both enalapril and
network from the tubules, resulting in insufficient perfu-the high dose of BMP-7. We also studied the effects of BMP-7
administration in a model streptozocin-induced diabetes. sion and a loss of transport efficiency. Another contribu-
Results. Treatment with BMP-7 in rats with ureteral obstruc- tor to the decline in renal function is the loss of tubule
tion of 3 days duration and subsequent release indicated that epithelial cells leading to tubule atrophy. Epithelial cellsthis compound decreases interstitial volume and accelerates
drop out due to transdifferentiation to fibroblasts andthe return of renal function. After 16 weeks of diabetes, the
by the process of apoptosis [5]. This loss of tubule cellsrats were treated with BMP-7. The administration of BMP-7
partially reversed renal hypertrophy, restored GFR to normal, leads to a permanent reduction of transport efficiency
and decreased proteinuria. even if the disruption of the interstitium is resolved,
Conclusions. These studies indicate that administration of
because the remaining epithelial cells have lost the abilityBMP-7 maintains and restores renal function and structure in
to replace themselves.animals with ureteral obstruction and diabetic nephropathy.
BONE MORPHOGENETIC PROTEINS
A variety of kidney diseases of glomerular or non-
In the past 20 years, members of one subgroup ofglomerular origin culminate in the expansion and fibrosis
the transforming growth factor- (TGF-) superfamily,of the tubulointerstitium space. Histologic grading of the
named generically bone morphogenetic proteins (BMP),fibrosis of the tubulointerstitium is more closely corre-
have been recognized as critical in controlling multiplelated with the loss of renal function than the histologic
organogenetic processes [6]. Comprising an ever-grow-grading of glomerulosclerosis [1]. Fibrosis, in general, is
ing number of identified homologs, the BMPs representsan expansion of stromal elements at the expense of
almost one third of the TGF- superfamily, with morehighly differentiated parenchymal cells within the tissue.
than 30 members already described. Individually, theThe architecture of the kidney entails an exquisite juxta-
members of this subfamily of secreted molecules areposition of post-glomerular capillaries surrounding the
termed either BMPs, osteogenic proteins (OPs), carti-tubules. This allows for the efficient transfer of fluid and
lage-derived morphogenetic proteins (CDMPs), or growthsolutes for reabsorption or secretion in order to maintain
and differentiation factors (GDFs). They have been clas-homeostasis. In renal disease, the expansion of stromal
sified into several subgroups according to their structuralelements disrupts the kidney architecture and, in all
similarities.probability, impairs fluid and solute exchange [2].
The molecular cloning of many BMP-encoding genesThe pathogenesis of end-stage renal disease (ESRD)
and their identification as TGF- relatives enhanced the
interest in these molecules and allowed expression and
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the nature of the assay that led to the identification of 2002 by the International Society of Nephrology
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these proteins, it became rapidly evident that their pat- leading to cell death of the metanephric mesenchymal
cells [9, 10]. A series of molecular analyses suggest thatterns of expression, as well as their physiological func-
tions, were not restricted to skeleton development. Other BMP-7 is one of the earliest glomeruli inducers. BMP-7
deficiency also causes, with incomplete penetrance, anfunctions of BMPs include cell proliferation and differ-
entiation, apoptosis, morphogenesis, patterning of vari- absence of lens induction and eye formation. This latter
phenotype is reminiscent of what is observed in BMP-4ous organs including the kidney and the skeleton, and
general organogenesis. deficient embryos. This is important as it suggests that, at
least during lens formation, redundancy between BMPs
may not prevent abnormalities to occur.
BONE MORPHOGENETIC PROTEIN-7
Following the action of the ureteric bud, the expression
BMP-7 is a member of the family whose broad expres- of BMP-7 continues at high levels in the collecting duct,
sion has been extensively studied [7, 8]. It starts to be and in cells of metanephric mesenchymal origin (glomer-
expressed during early gastrulation, localizing in the ec- ular podocytes). The expression of BMP-7 persists in the
toderm of the periphery of the embryo. At 8.5 and 9.5 kidney after adulthood. Since renal injury can decrease
days postcoitum (dpc), BMP-7 is strongly expressed in the expression of BMP-7, we postulated that replace-
the surface ectoderm and the notochord, in the neuroepi- ment therapy with this compound would be efficacious.
thelium extending toward the prospective forebrain, and
in the developing gut [7]. BMP-7 is also expressed in the The effects of BMP-7 in ureteral obstruction
atrial and ventricular chambers. This expression in the Tubulointerstitial fibrosis is a major component of sev-
heart continues throughout development. During eye eral kidney diseases associated with progression to end-
development, BMP-7 expression is detected in the sur- stage renal failure. We found that BMP-7, also known
face ectoderm, the lens placode, and the optic vesicle as osteogenic protein-1 (OP-1), when administered at the
[7]. In the developing skeleton, BMP-7 is expressed in time of unilateral ureteral obstruction (UUO) and every
the developing limb, in the mesenchymal cells localized other day at doses of 100 or 300 g/kg body wt in rats
between the developing digits, and in the chondrogenic prevented interstitial inflammation and fibrogenesis. The
zones. BMP-7 is also expressed in many cells of the administration of BMP-7 blunted tubular atrophy, an
developing kidney, where it plays a critical role (dis- effect that was not shared with the angiotensin con-
cussed later in this article). At 9.5 dpc, BMP-7 transcripts verting enzyme (ACE) inhibitor enalapril. BMP-7 ad-
are detected in the wolffian ducts, which give rise to the ministration blocked the stimulation of epithelial cell
ureteric buds. At 12.5 dpc, BMP-7 is expressed predomi- apoptosis produced by UUO, resulting in maintenance
nantly in the ureteric bud epithelium, but a weaker ex- of tubular epithelial integrity. Administration of BMP-7
pression is also detected in the surrounding condensed also preserved renal blood flow [11].
mesenchymal cells. Later on, its transcripts are present In a subsequent study, we extended the prevention
in the same structures, but also in the peritubular aggre- protocol by using a treatment protocol to examine if
gates and the podocytes of the glomeruli. No expression BMP-7 was beneficial at limiting fibrosis of the kidney
was detected in the comma- and S-shaped bodies [9, 10]. when the compound was administered during the pro-
Consistent with their wide pattern of expression, muta- gression of fibrotic disease [12]. Animals were ascribed
tions in BMP-encoding genes can affect many organoge- to one of four groups. Group 1 received vehicle, group
netic processes. Some of these mutations cause early 2 received 12.5 mg/kg body wt/day enalapril, group 3
embryonic lethality, precluding for now the analysis of received 50 or 300 g/kg body wt BMP-7, and group 4
the role of these proteins during skeleton development. received both the enalapril and the high dose of BMP-7.
We review briefly some of these phenotypes, with a par- Rats underwent UUO for 3 days after which the obstruc-
ticular emphasis on BMP-7, a gene product required for tion was relieved. In the treatment protocol, 300 g/kg
glomeruli formation. Again, the purpose of this enumer- body wt BMP-7 was given after the release of obstruc-
ation is to highlight the difference between the wealth tion. Seven days after release of the obstruction and
of their biologic function and the remarkable pharmacol- the onset of treatment, glomerular filtration rate (GFR),
ogy of this group of molecules. renal blood flow (RBF), and various histologic indices
The depletion of the gene encoding BMP-7 causes a of fibrosis were determined. On a consistent basis, BMP-
perinatal lethality in mice caused by uremia. In the ab- 7 treatment alone was found to be slightly but signifi-
sence of BMP-7, there is a failure of kidney morphogene- cantly (P  0.04–0.007) better than enalapril alone, or
sis, the deficient mice exhibiting small dysgenic kidneys in combination with enalapril at decreasing interstitial
that have less than 3 glomeruli per histologic section volume or tubule atrophy. BMP-7 treatment was effec-
compared with approximately 100 in normal mice. This tive and slightly better than enalapril at restoring GFR
defect was tracked down to an epithelial-mesenchymal in the prevention protocol. Treatment with BMP-7 sig-
nificantly increased GFR (P  0.01) above that seeninteraction occurring between 12.0 and 12.5 dpc and
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Table 2. Glomerular filtration rate and renal blood flowTable 1. Tubule diameter
Sham 714 GFR RBF
Vehicle-treated 536a
Sham 0.340.07 1.020.06Enalapril-treated 595b
Vehicle-treated 0.160.02a 0.830.22BMP-7-treated 654c
Enalapril-treated 0.210.05a 0.920.23Enalapril and BMP-7-treated 595b
BMP-7-treated 0.260.06b 0.930.24
Values are in micrometers. The tubule diameters of the contralateral unob- Enalapril and BMP-7-treated 0.270.13 1.010.49
structed kidneys were not significantly different from the value of the kidneys
Values are mL/min/100 g body weight. The GFR of the contralateral unob-of sham-operated animals.
structed kidneys varied between 0.35  0.08 and 0.47  0.13. This was nota P  0.0005 vs. sham
significantly different from the GFR of the kidneys of sham-operated animalsb P  0.01 vs. sham
P  0.08 to 0.75. The RBF of the contralateral unobstructed kidneys variedc P  0.05 vs. sham, P  0.002 vs. vehicle, P  0.04 vs. enalapril or enalapril
between 1.17  0.28 to 1.48  0.19.and BMP-7
a P  0.02 vs. sham
b P  0.01 vs. vehicle and P  0.10 vs. sham
with vehicle treatment. These results suggest that BMP-7
treatment is capable of blunting the progression of fi- BMP-7 (10, 30, or 100 g/kg IV, biw), enalapril (100
brotic disease, and also decreasing interstitial volume. mg/L in the drinking water), or vehicle was begun at 16
Importantly, a return of renal function is accelerated by weeks. At 32 weeks the parameters shown in Table 3
BMP-7 treatment. These results suggest that administra- were measured. There were no differences in weight gain,
tion of BMP-7 may be an effective treatment to restore blood glucose levels, and insulin doses among the different
or preserve renal histology and renal function in this groups during the subsequent 16 weeks of treatment
experimental model of renal disease. (abstract; Wang et al, J Am Soc Nephrol 12:850A, 2001).
In a previous study [11] that utilized a rat model of BMP-7 therapy partially reversed renal hypertrophy,
unilateral ureteral obstruction, we found that BMP-7 restored GFR to normal, and also decreased proteinuria.
administration blunted renal fibrosis when given in a Marked amelioration of glomerular pathology with re-
prevention protocol. In that model, the renal disease was ductions in glomerular area, decrease in tubulointersti-
severe and renal function was not measurable in a control tial volume, and elimination of FGS were observed in
group of animals. Administration of BMP-7 partially animals treated with 100 g/kg BMP-7. Intermediate ef-
restored renal function. In the present investigation, the fects in all parameters were observed in the 30 and 10
period of ureteral obstruction was shortened from five g/kg BMP-7 treatment groups in the kidney. Recently,
to three days in order to consistently obtain measures Hirschberg and co-workers reported that BMP-7 protein
of glomerular filtration rate and renal blood flow. The and mRNA were significantly decreased by 15 weeks
effect of BMP-7 treatment to influence renal architecture after STZ treatment in the rat and declined further by
and function was determined and was compared with the 30 weeks [13]. We conclude that BMP-7 can reverse DM-
prevention protocol with enalapril. More significantly, induced glomerular hypertrophy and injury, generally out-
the effect of BMP-7 treatment to restore renal function, performing the effects of enalapril. These studies suggest
after renal disease had progressed, was also determined. that BMP-7 may be a potent new therapeutic agent in
Table 1 shows the tubular diameter of sham (unob- chronic kidney disease, especially diabetic nephropathy.
structed kidneys), vehicle-treated rats with ureteral ob- Gould et al [14] found that BMP-7 expression was
struction, enalapril-treated rats with obstruction and higher in the medullary region of the kidney when com-
BMP-7-treated rats with obstruction. Table 2 depicts the pared with the cortical region. BMP-7 has been detected
volume for GFR and RBF in the different groups of rats. in the tubular epithelium of the thick ascending limb,
distal convoluted tubule, collecting duct, and podocytes
Effect of BMP-7 in diabetic nephropathy within the glomerulus. Gould also found that BMP-7
Because of the remarkable effectiveness of BMP-7 reduced the basal and tumor necrosis factor- (TNF-)
administration in the model of ureteral obstruction, stimulated expression of interleukin-6, interleukin-1,
we questioned the potential benefit of this compound in monocyte chemotactic protein 1 (MCP-1), and interleu-
a model of chronic progressive kidney disease. Thus, kin-8. These findings suggest that BMP-7 limits the in-
we undertook a study of BMP-7 therapy in diabetic- flammatory response. High levels of MCP-1 have been
nephropathy. We used STZ induced diabetes to test this found in diseased renal tissue supporting the role of this
hypothesis because this model is well established. After chemokine in renal inflammation and interstitial fibrosis.
a single dose of STZ (62 mg/kg), diabetic animals were In summary, it has been demonstrated that BMP-7
treated with insulin to maintain blood sugar between maintains renal function in animal models with acute
300–500 mg/dL. After 16 weeks, kidney weight was in- and chronic renal disease (acute renal failure, ureteral
creased 1.8-fold in DM, GFR was increased 3.2-fold, and obstruction, and diabetic nephropathy). In these animals
treatment with BMP-7 increases epithelial cell survivalprotein excretion was 35.6 23.1 mg/24 h. Therapy with
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Table 3. Effects of BMP-7 or enalapril in rats with diabetic nephropathy
Kidney wt GFR Proteinuria Glom area
g mL/min/100 g BW mg/24 h 104 um2
Int vol FSGS
%
DM 16 weeks 1.420.04 1.560.46 35.623.1
DM 32 weeks
vehicle 1.330.18 0.380.07 128.9149.1 1.280.23 13.152.85 12.667.23
DM 32 weeks
BMP-7 100 g/kg 1.100.10b 0.700.23c 14.39.9 1.090.18a 10.552.70c 4.074.94c
DM 32 weeks
enalapril 1.090.09b 0.580.15 33.621.4 1.180.22c 11.852.48 5.245.04c
a P  0.001, b P  0.01, c P  0.05 compared to 32 weeks vehicle
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